Stockscreener 앱 받기
64.47
1.61%
1.02
시간 외 거래:
64.84
0.37
+0.57%
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
Halozyme Therapeutics, Inc. $HALO Shares Bought by HRT Financial LP - MarketBeat
Did Patent Win and Jim Lang’s Arrival Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative? - simplywall.st
BI Asset Management Fondsmaeglerselskab A S Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Stock Report: What catalysts could drive Halozyme Therapeutics Inc stock higherJuly 2025 Intraday Action & Verified Stock Trade Ideas - moha.gov.vn
Halozyme Elects James Lang to Board of Directors - TipRanks
Smart Money: Is Halozyme Therapeutics Inc stock overvalued by current metricsQuarterly Market Summary & High Yield Stock Recommendations - moha.gov.vn
Halozyme Therapeutics, Inc. $HALO Shares Sold by Gabelli Funds LLC - MarketBeat
First Trust Advisors LP Decreases Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics awards performance-based stock units to CEO By Investing.com - Investing.com Canada
Halozyme Approves Stock Grant for CEO Incentive - TipRanks
Halozyme Therapeutics awards performance-based stock units to CEO - Investing.com
(HALO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - sharewise.com
Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 - MSN
Marshall Wace LLP Has $20.24 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2Xideas AG Sells 62,256 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
James Lang elected to Halozyme Therapeutics board of directors By Investing.com - Investing.com Canada
James Lang elected to Halozyme Therapeutics board of directors - Investing.com
Halozyme Therapeutics Elects New Board Member - TradingView
Jim Lang elected to Halozyme’s board of directors - Investing.com
Jim Lang elected to Halozyme’s board of directors By Investing.com - Investing.com India
Jim Lang Elected to Halozyme's Board of Directors - PR Newswire
Halozyme and Quinn Emanuel secure PI against MSD over Keytruda SC - JUVE Patent
Cash per share of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Halozyme wins German injunction blocking Merck’s Keytruda distribution - Indian Pharma Post
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Halozyme Therapeutics (HALO): Reassessing Valuation After Strong Year-To-Date Gains And Recent Momentum Slowdown - Yahoo Finance
Norges Bank Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. - Finviz
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Epoch Investment Partners Inc. Sells 195,366 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Kennedy Capital Management LLC Has $21.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group - MarketBeat
Citizens reiterates Market Outperform rating on Halozyme stock amid legal win - Investing.com
Why Halozyme Therapeutics Inc. stock could rally in 20252025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Merck suffers a setback over its new Keytruda formulation in Germany - statnews.com
Halozyme Therapeutics Inc RV7 Stock Analysis and ForecastPrice Action Analysis & The Smart Money Is Buying These Picks - earlytimes.in
Halozyme (HALO) Wins Injunction Against Merck in Germany - GuruFocus
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesTrade Risk Summary & Expert Curated Trade Setup Alerts - Newser
Halozyme (NASDAQ: HALO) gets German court order halting Keytruda SC over MDASE patent - Stock Titan
Do Halozyme Therapeutics’ (HALO) Deals And Insider Sales Clarify Or Complicate Its Royalty Story? - Sahm
0.39%
1.90%
자본화:
|
볼륨(24시간):